MedTrace Logo

Improving the Effect of Multiple Sclerosis Drugs by Chronobiology

NCT06385197 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-05-06

No results posted yet for this study

Summary

A trial for evaluating the ability to improve the effect of dimethyl fumarate in patients with Multiple Sclerosis (MS) by chronobiology A controlled-randomization dosing regimen administered to patients with MS and provided by a designated app. The treatment limitations of time interval is pre-defined according to approved therapeutic windows.

Conditions

Interventions

DEVICE

App randomizing dosing regimen

patients will receive their dimethyl fumarate treatment and the dose and time of administration will be determined using a designated app.

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • yoav hershkovtiz, md · Hadassah Medical Organization

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-08
Primary Completion
2023-06-01
Completion
2023-06-02

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06385197 on ClinicalTrials.gov